1406. Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Children in the Pediatric Intensive Care Unit
Session: Poster Abstract Session: PK/PD Studies
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • ARCAG 2018_9_27_18 POSTER JLV_Draft Edit jle_SNA_JR1_final.pdf (857.6 kB)
  • Background: Augmented renal clearance (ARC) in critically-ill pediatric patients has been evaluated in limited studies. We evaluated ARC using clearance of aminoglycosides (CLAMINO) derived from population-based pharmacokinetic modeling.

    Methods: A retrospective, cohort study was conducted at 2 pediatric hospitals in patients who received aminoglycosides from 1999 to 2016. ARC was defined as a CLAMINO of ≥ 130 mL/min/1.73m2 within the first 24hrs of therapy. Pharmacokinetic (PK) models with nonparametric parameter estimation were constructed using Pmetrics in R, with the ultimate model selected by Akaike score and rule of parsimony. Covariate modifiers considered included: age, total body weight (TBW), serum creatinine (SCr) and sex. Noncompartmental analysis was performed on the Bayesian posteriors from the first dose to generate CLAMINO within the first 24hrs and other PK exposure metrics (i.e. area under the curve for first 24hrs [AUC24], maximum concentration [CMAX]). Summary of patient demographics and statistical analysis were performed using GraphPad Prism version 7.

    Results: ARC was identified in 34 of 117 (29%) subjects using 275 aminoglycoside serum concentrations. A 2-compartment model fit the data well (See Figure 1: Population [a], Bayesian [b]). Allometric scaling of CLAMINO utilized a fixed exponent of 0.75 and volume of distribution (VD) scaling utilized a fixed exponent of 1 in the final model. The final population model for CLAMINO (L/hr) was 3.45 * (TBW/40)0.75 + 0.05 * 10(SCr/AGE and VD was 10.64 * (TBW/40)1. Median age and baseline SCr were similar in those with and without ARC (13 [IQR 10-16] vs 11.0 [5.0-15.0] yrs., p=0.11, and 0.37 [0.27-0.49] vs 0.38 [0.28-0.50] mg/dL, p=0.67, respectively). Median TBW was found to be significantly higher in those with vs without ARC (44.9 [26.9-61.7] vs 34 [17.6-54.9] kg p=0.04). Median 24hr CLAMINO was also found to be significantly higher in those with vs without ARC (147.3 [138.7-163.9] vs 94.5 [79.4-112.9], ml/min/1.73m2, p<0.001). Patients with vs without ARC had significantly lower AUC24 and CMAX (40.7 [33.3-54.4] vs 55.7[46.7-66.4] mg*hr/L, p=<0.001 and 5.06 [4.11-6.76] vs 6.32 [5-7.44], µg/mL, p=0.01).

    Conclusion: The incidence of ARC observed was similar to adult studies. Patients that exhibited ARC had lower AUC24 and CMAX; thus, higher doses may be warranted.
     

    Sean Avedissian, Pharm.D.1, Nathaniel Rhodes, PharmD, MSc2, Yuna Kim, BS3, Josh Valdez, BS3, John Bradley, MD, FAAP4 and Jeniffer Le, Pharm.D., MAS, FCCP, FCSHP, BCPS-ID5, (1)Pharmacy Practice, Midwestern University Chicago College of Pharmacy/Northwestern Memorial Hospital, Downers Grove, IL, (2)Department of Pharmacy, Northwestern Medicine, Chicago, IL, (3)University of California San Diego Skaggs School of Pharmacy, San Diego, CA, (4)Pediatric Infectious Disease, University of California San Diego, San Diego, CA, (5)Pharmacy/Infectious Diseases, University of California, San Diego Skaggs School of Pharmacy, La Jolla, CA

    Disclosures:

    S. Avedissian, None

    N. Rhodes, None

    Y. Kim, None

    J. Valdez, None

    J. Bradley, None

    J. Le, None

    See more of: PK/PD Studies
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.